TALOPH(SH:600222) Xin Lang Cai Jing·2025-10-30 02:23Core Insights - TaiLong Pharmaceutical (600222.SH) reported a total revenue of 1.187 billion yuan for Q3 2025, ranking 29th among disclosed peers, which is a decrease of 154 million yuan or 11.47% year-on-year [1] - The net profit attributable to shareholders was 25.33 million yuan, ranking 41st among peers, down by 3.57 million yuan or 12.36% compared to the same period last year [1] - The company experienced a net cash outflow from operating activities of 88.99 million yuan, ranking 55th among peers, but this represents an increase of 7.73 million yuan year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 55.88%, ranking 53rd among peers, which is an increase of 2.12 percentage points from the previous quarter but a decrease of 0.63 percentage points year-on-year [3] - The gross profit margin is 24.29%, ranking 54th among peers, down by 0.40 percentage points from the previous quarter and down by 2.20 percentage points year-on-year [3] - The return on equity (ROE) is 1.59%, ranking 42nd among peers, which is a decrease of 0.25 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.05 yuan, ranking 39th among peers, which is a decrease of 0.01 yuan or 11.75% year-on-year [3] - The total asset turnover ratio is 0.33 times, ranking 32nd among peers, down by 0.04 times year-on-year, representing a decline of 10.57% [3] - The inventory turnover ratio is 2.12 times, ranking 14th among peers, which is an increase of 0.10 times or 5.03% year-on-year [3] Shareholder Structure - The number of shareholders is 40,400, with the top ten shareholders holding 168 million shares, accounting for 29.31% of the total share capital [3] - The largest shareholder is Zhengzhou TaiRong Industrial Investment Co., Ltd., holding 14.37% of the shares [3] - Other notable shareholders include Zhengzhou Zhongsheng Industrial Group Co., Ltd. with 8.71% and Wu Lan with 1.38% [3]